Skip to main content

Espinoza Octavio's Form 4 filing

Ligand Pharmaceuticals IncLGND · filed May 13, 2025

Accession no.
0002001011-25-000028
Filed
May 13, 2025
Trade date
May 9, 2025
Filing delay
4 days
Rule 10b5-1 plan
Not checked

This filing lists 2 non-derivative transactions. Open-market purchases total $156.1K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Espinoza OctavioCIK 0001905248Officer (Chief Financial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 9, 2025Common StockPPurchaseAcquired+1,000$103.89+$103,89027,432Direct
May 9, 2025Common StockPPurchaseAcquired+500$104.40+$52,20027,932Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)